FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W49953563> ?p ?o ?g. }

• W49953563 endingPage "2526" @default.
• W49953563 startingPage "2520" @default.
• W49953563 abstract "Abstract Between 1982 and 1986, 326 evaluable patients with acute myeloid leukemia (AML) were randomized to receive cytarabine (Ara-C) at 200 mg/m2 (A200) or 100 mg/m2 (A100) for induction and maintenance therapy. Cycle 1 of induction therapy consisted of 7 days of continuous intravenous (IV) Ara-C and 3 days of i.v. daunorubicin (DNR); cycle 2, if needed, consisted of 5 days of Ara-C and 2 days of DNR. Complete responders (CR) then received monthly subcutaneous (SC) Ara-C at the respective doses (A100 or A200) with 6-thioquanine (6TG) at months 1 and 5, with vincristine (VCR) and prednisone at months 2, 4, 6, and 8, and with DNR at months 3 and 7. Complete response rates were 58% (A100) and 64% (A200) (P = .29). Median survival was 46 weeks (A100) and 38 weeks (A200) (P = .64); 5-year survival was 10% (A200) and 8% (A100). Median time to remission was 6.7 weeks (A200) and 8.1 weeks (A100) (P = .18). Median disease-free survival was 41 weeks (A200) and 44 weeks (A100) (P = .86). Deaths were attributed to therapy-related toxicities in 21% (A200) and 13% (A100) (P = .05). The 5-year survival was 15% for patients with performance status (PS) 0, 8% for PS 1 to 2, and 2% for PS 3 to 4, 18% for patients less than 40 years, 8% for ages 40 to 59, and 3% for age 60 or greater. Stratification of data by age and PS suggested that A200 may improve survival in patients less than 60 years with a good PS 0 (P = .05). This trial does not support the superiority of A200 over A100 in the treatment of AML." @default.
• W49953563 created "2016-06-24" @default.
• W49953563 creator A5007613973 @default.
• W49953563 creator A5011318487 @default.
• W49953563 creator A5013377891 @default.
• W49953563 creator A5021092277 @default.
• W49953563 creator A5028692573 @default.
• W49953563 creator A5031875226 @default.
• W49953563 creator A5051170847 @default.
• W49953563 creator A5053972976 @default.
• W49953563 creator A5069229273 @default.
• W49953563 creator A5088376613 @default.
• W49953563 date "1991-11-15" @default.
• W49953563 modified "2023-09-29" @default.
• W49953563 title "A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B" @default.
• W49953563 cites W1481564836 @default.
• W49953563 cites W1483770518 @default.
• W49953563 cites W1493398929 @default.
• W49953563 cites W1897993962 @default.
• W49953563 cites W1965377737 @default.
• W49953563 cites W1979300931 @default.
• W49953563 cites W2006413929 @default.
• W49953563 cites W2022315900 @default.
• W49953563 cites W2056809896 @default.
• W49953563 cites W2076426515 @default.
• W49953563 cites W2078077818 @default.
• W49953563 cites W2090653702 @default.
• W49953563 cites W2187668060 @default.
• W49953563 cites W2211072972 @default.
• W49953563 cites W2345454632 @default.
• W49953563 cites W2409849732 @default.
• W49953563 cites W2442889811 @default.
• W49953563 cites W2468642970 @default.
• W49953563 doi "https://doi.org/10.1182/blood.v78.10.2520.2520" @default.
• W49953563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1824249" @default.
• W49953563 hasPublicationYear "1991" @default.
• W49953563 type Work @default.
• W49953563 sameAs 49953563 @default.
• W49953563 citedByCount "168" @default.
• W49953563 countsByYear W499535632012 @default.
• W49953563 countsByYear W499535632013 @default.
• W49953563 countsByYear W499535632014 @default.
• W49953563 countsByYear W499535632015 @default.
• W49953563 countsByYear W499535632016 @default.
• W49953563 countsByYear W499535632017 @default.
• W49953563 countsByYear W499535632018 @default.
• W49953563 countsByYear W499535632019 @default.
• W49953563 countsByYear W499535632020 @default.
• W49953563 countsByYear W499535632021 @default.
• W49953563 countsByYear W499535632022 @default.
• W49953563 crossrefType "journal-article" @default.
• W49953563 hasAuthorship W49953563A5007613973 @default.
• W49953563 hasAuthorship W49953563A5011318487 @default.
• W49953563 hasAuthorship W49953563A5013377891 @default.
• W49953563 hasAuthorship W49953563A5021092277 @default.
• W49953563 hasAuthorship W49953563A5028692573 @default.
• W49953563 hasAuthorship W49953563A5031875226 @default.
• W49953563 hasAuthorship W49953563A5051170847 @default.
• W49953563 hasAuthorship W49953563A5053972976 @default.
• W49953563 hasAuthorship W49953563A5069229273 @default.
• W49953563 hasAuthorship W49953563A5088376613 @default.
• W49953563 hasBestOaLocation W499535631 @default.
• W49953563 hasConcept C126322002 @default.
• W49953563 hasConcept C141071460 @default.
• W49953563 hasConcept C2776694085 @default.
• W49953563 hasConcept C2776755627 @default.
• W49953563 hasConcept C2778041864 @default.
• W49953563 hasConcept C2778461978 @default.
• W49953563 hasConcept C2778720950 @default.
• W49953563 hasConcept C2778729363 @default.
• W49953563 hasConcept C2779429289 @default.
• W49953563 hasConcept C2781021840 @default.
• W49953563 hasConcept C71924100 @default.
• W49953563 hasConcept C90924648 @default.
• W49953563 hasConceptScore W49953563C126322002 @default.
• W49953563 hasConceptScore W49953563C141071460 @default.
• W49953563 hasConceptScore W49953563C2776694085 @default.
• W49953563 hasConceptScore W49953563C2776755627 @default.
• W49953563 hasConceptScore W49953563C2778041864 @default.
• W49953563 hasConceptScore W49953563C2778461978 @default.
• W49953563 hasConceptScore W49953563C2778720950 @default.
• W49953563 hasConceptScore W49953563C2778729363 @default.
• W49953563 hasConceptScore W49953563C2779429289 @default.
• W49953563 hasConceptScore W49953563C2781021840 @default.
• W49953563 hasConceptScore W49953563C71924100 @default.
• W49953563 hasConceptScore W49953563C90924648 @default.
• W49953563 hasIssue "10" @default.
• W49953563 hasLocation W499535631 @default.
• W49953563 hasOpenAccess W49953563 @default.
• W49953563 hasPrimaryLocation W499535631 @default.
• W49953563 hasRelatedWork W2030997447 @default.
• W49953563 hasRelatedWork W2135404678 @default.
• W49953563 hasRelatedWork W2404722194 @default.
• W49953563 hasRelatedWork W2414858770 @default.
• W49953563 hasRelatedWork W2418628712 @default.
• W49953563 hasRelatedWork W2424199172 @default.
• W49953563 hasRelatedWork W2473004890 @default.
• W49953563 hasRelatedWork W2889338028 @default.

• next